Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approvals from the USFDA for Phytonadione Tablets and Colchicine Tablets21-02-2019
21-02-2019
Cadila Healthcare Ltd - 532321 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
The Company proposes to pass two special resolutions as per the attached Postal Ballot Notice.16-02-2019
CADILA HEALTHCARE LTD. - 532321 - Notification
Company's purified chick embryo cell rabies vaccine, Vaxirab N, has received the prequalification from the World Health Organisation (WHO). The group had received the prequalification from the WHO for its purified duck embryo rabies vaccine, Lyssavac N, for purchase by various United Nations Agencies, in 2008. Subsequently, the company migrated to the purified chick embryo cell rabies vaccine, Vaxirab N, which received the WHO prequalification on 7th February 2019.15-02-2019
Consumer healthcare industry ready to take off'
Consumer healthcare products have been the focus of the market lately. In 2018, Zydus Cadila bought Kraft Heinz's consumer brand businesses, which inc13-02-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Triamterene and Hydrochlorothiazide Capsules USP13-02-2019
Zydus Cadila gets USFDA nod for drug to treat seizures
Zydus Cadila on Friday said it has received final approval from the US health regulator to market Carbamazepine extended-release tablets, used to tre08-02-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Carbamazepine Extended-Release Tablets USP08-02-2019
Cadila Healthcare Ltd - 532321 - Change In Authority
Change in authority to disclose material event to stock exchanges due to change in Company Secretary07-02-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
Resignation of Mr. Upen Shah and appointment of Mr. Dhaval N. Soni as the Company Secretary of the Company.07-02-2019
Cadila Healthcare Ltd - 532321 - Unaudited Financial Results For The Quarter / Nine Months Ended On December 31, 2018
Unaudited financial results for the quarter / nine months ended on December 31, 2018 along with limited review report and press release.07-02-2019